Breast Cancer Clinical Trial
Official title:
Phase Ⅱ Study of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer
Breast cancer is a heterogeneous disease and can be classified into several distinctive
subgroups. Triple-negative breast cancer(TNBC) is defined by lack of estrogen(ER),
progesterone(PR) immunoreactivity and lack of human epidermal receptor-2(HER2)
overexpression. TNBC comprises around 15% of all breast cancer and is characterized by its
aggressive clinical behavior and insensitivity toward available targeted treatment
strategies such as endocrine and anti-HER2 therapies.Although TNBC is sensitive to
chemotherapy,early relapse with metastatic disease is common and the prognosis is poor.
Development Of novel treatment strategies is,therefore,needed and the study of other
potential targets in TNBC,like tyrosine kinase receptors,is a topic of interest.
Epidermal Growth Factor Receptor(EGFR) is a transmembrane receptor tyrosine kinase that
encoded by cell erythroblastosis virus oncogene B1(C-erbB1) and belongs to the
HER/Erythroblastosis virus oncogene B(ErbB) family. By several signal pathways,EGFR
regulates cell proliferation, differentiation, apoptosis, invasion,and angiogenesis,and
serves as a poor prognostic factor.EGFR is overexpressed in a variety of malignancies
including TNBC.Gene expression profiling and immunohistochemical studies have indicated that
40 to 60% of TNBCs exhibit EGFR expression and gene amplification was found in 18% of this
subgroup,but EGFR mutation was rare in TNBC.
By far,the role of gefitinib, an EGFR tyrosine kinase inhibitor(TKI),in the metastatic TNBC
has not been identified. Most clinical trials about EGFR TKIs in the breast cancer have one
or more limitations including:1) the study population had received heavily pretreatment;
2)the enrolled patients included several subgroups of breast cancer; 3)the expression of
EGFR was not clear in the enrolled patients.
Here, the investigators launch a prospective clinical trial, and about 50 patients with
triple-negative,EGFR positive metastatic breast cancer that have received at least second
line therapy will be enrolled. these patients will be treated with gefitinib, the toxicity
and effects of gefitinib will be recorded prospectively to evaluate the role of gefitinib in
the metastatic TNBC.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |